With a truly patient-focussed approach we offer a best-in-class Early Access Program service that ensures patient, healthcare professional, and client needs are met through passionate and tailored program delivery.
Sourcing commercial drug products for clinical trials can be a complex process and is often one of the last considerations during study design. Our experienced Global Sourcing Team is uniquely positioned to support you through the commercial drug sourcing process with their deep understanding of clinical trials and commercial drug markets.
In this podcast, Maya Zlatanova sits down with Naomi Litchfield, Director of Patient Advocacy at Bionical Emas, to explore the life‑changing impact of Early Access Programs (EAPs). Naomi shares how her personal journey, after her sister survived four rare cancers thanks to an early access medicine, fuels her passion for expanding access to investigational treatments.
Together, they break down what EAPs are (also known as Expanded Access or Compassionate Use), who is eligible, and why these programs matter for patients who have exhausted all other treatment options. Naomi explains the key differences between clinical trials and EAPs, why EAPs cannot be promoted, and why requests must come unsolicited from healthcare professionals. She also highlights the potential for data collection through EAPs to support real world understanding of investigational treatments.
